Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TNX-1500,Undisclosed
Therapeutic Area : Nephrology
Study Phase : Preclinical
Recipient : Tonix Pharmaceuticals Holding Corp
Deal Size : Undisclosed
Deal Type : Collaboration
Tonix, Makana Partner On Anti-CD40L Antibody and Xenotransplantation
Details : Tonix and Makana will study Tonix’s anti-CD40L monoclonal antibody candidate, TNX-1500, in combination with Makana’s human-compatible organs and cells for the treatment of organ failure.
Product Name : TNX-1500
Product Type : Antibody
Upfront Cash : Undisclosed
April 09, 2025
Lead Product(s) : TNX-1500,Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Recipient : Tonix Pharmaceuticals Holding Corp
Deal Size : Undisclosed
Deal Type : Collaboration